2-(4-([1,1'-biphenyl]-2-carboxamido)phenyl)acetic acid | 833485-27-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-([1,1'-biphenyl]-2-carboxamido)phenyl)acetic acid
• 英文别名: 2-[4-[(2-Phenylbenzoyl)amino]phenyl]acetic acid
• CAS: 833485-27-1
• 化学式: C₂₁H₁₇NO₃
• 分子量: 331.371
• InChiKey: YZONYMHBWXQGGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  ethyl 2-(4-([1,1'-biphenyl]-2-carboxamido)phenyl)acetate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 以42%的产率得到2-(4-([1,1'-biphenyl]-2-carboxamido)phenyl)acetic acid
  参考文献：
  名称：

  Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists

  摘要：

  Activation of the nuclear farnesoid X receptor (FXR) which acts as cellular bile acid sensor has been validated as therapeutic strategy to counter liver disorders such as non-alcoholic steatohepatitis by the clinical efficacy of obeticholic acid. FXR antagonism, in contrast, is less well studied and potent small molecule FXR antagonists are rare. Here we report the systematic optimization of a novel class of FXR antagonists towards low nanomolar potency. The most optimized compound antagonizes baseline and agonist induced FXR activity in a full length FXR reporter gene assay and represses intrinsic expression of FXR regulated genes in hepatoma cells. With this activity and a favorable toxicity-, stability- and selectivity-profile it appears suitable to further study FXR antagonism in vitro and in vivo.

  DOI：

  10.1016/j.bmc.2018.07.017

文献信息

• [EN] BENZOIC AND PHENYL ACETIC ACID DERIVATIVES AS HNF-4 MODULATORS<br/>[FR] DERIVES D'ACIDE BENZOIQUE ET PHENYLACETIQUE UTILISES EN TANT QUE MODULATEURS DES RECEPTEURS DU FACTEUR HNF-4 DOLLAR G(A)
  申请人：LIGAND PHARMACUETICALS INC

  公开号：WO2005009104A2

  公开（公告）日：2005-02-03

  The present invention is directed to hepatocyte nuclear factor 4a (HNF-4a) receptor modulator compounds. This invention is also directed to pharmaceutical compositions containing such compounds as well as methods of using such compounds and pharmaceutical compositions for modulating HNF-4a receptors as well as processes mediated by HNF-4a receptors. Also provided are methods of making such compounds and pharmaceutical compositions, as well as intermediates used in their synthesis.